Debasish Hota

Prof. Dr. Debasish Hota


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 May 2021 in Journal of Diabetes
Verified
Journal Article
Closed access
PDF file
ASAnand Srinivasan
Anand Srinivasan
PDPinaki Dutta
Pinaki Dutta
DBDipika Bansal
Dipika Bansal
ACAmitava Chakrabarti
Amitava Chakrabarti
ABAnil Kumar Bhansali
Anil Kumar Bhansali
DHDebasish Hota
Debasish Hota

15 May 2015 in Diabetes Research and Clinical Practice
Verified
Journal Article
Closed access
PDF file
SRSujit Rajagopalan
Sujit Rajagopalan
PDPinaki Dutta
Pinaki Dutta
DHDebasish Hota
Debasish Hota
ABAnil Bhansali
Anil Bhansali
ASAnand Srinivasan
Anand Srinivasan
ACAmitava Chakrabarti
Amitava Chakrabarti

5 September 2011 in Fundamental & Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
PDPuneet Dhamija
Puneet Dhamija
DBDipika Bansal
Dipika Bansal
ASAnand Srinivasan
Anand Srinivasan
ABAshish Bhalla
Ashish Bhalla
DHDebasish Hota
Debasish Hota
ACAmitava Chakrabarti
Amitava Chakrabarti

17 July 2023 in Journal of the American Nutrition Association
Verified
Journal Article
Closed access
DHDebasish Hota
Debasish Hota
BPBiswa M. Padhy
Biswa M. Padhy
RMRituparna Maiti
Rituparna Maiti
DBDebasis Bisoi
Debasis Bisoi
JSJYOTI PRAKASH SAHOO
JYOTI PRAKASH SAHOO
DBDebasis Bagchi
Debasis Bagchi
Trigonella foenum-graecum (Fenugreek) is an extensively researched phytotherapeutic for the management of Type 2 diabetes without any associated side effects. The major anti-diabetic bioactive constituents present in the plant are furostanolic saponins, which are more abundantly available in the seed of the plant. However, the bioavailability of these components depends on the method of extraction and hence formulation of the phytotherapeutic constitutes a critical step for its success. The present study reports the efficacy of a novel, patented fenugreek seed extract, Fenfuro®, containing significant amount of furostanolic saponins, in an open-labelled, two-armed, single centric study on a group of 204 patients with Type 2 diabetes mellitus over a period of twelve consecutive weeks. Administration of Fenfuro® in the dosage of 500 mg twice daily along with metformin and/or sulfonylurea-based prescribed antidiabetic drug resulted in a reduction of post-prandial glucose by more than 33% along with significant reduction in fasting glucose, both of which were greater than what resulted for the patient group receiving only Metformin and/or Sulfonylurea therapy. Fenfuro® also resulted in reduction in mean baseline HOMA index from 4.27 to 3.765, indicating restoration of insulin sensitivity which was also supported by a significant decrease in serum insulin levels by >10% as well as slight reduction in the levels of C-peptide. However, in the case of the Metformin and/or Sulfonylurea group, insulin levels were found to increase by more than 14%, which clearly indicated that drug-induced suppression of glucose levels instead of restoration of glucose homeostasis. Administration of the formulation was also found to be free from any adverse side effects as there were no changes in hematological profile, liver function and renal function. The study demonstrated the promising potential of this novel phytotherapeutic, Fenfuro®, in long-term holistic management of type-2 diabetes.

16 November 2024 in Microbiology Research
Verified
Journal Article
Open access
PDF file
AMArchana Mishra
Archana Mishra
SJSaubhagya Kumar Jena
Saubhagya Kumar Jena
ASAnand Srinivasan
Anand Srinivasan
ATAmruta Tripathy
Amruta Tripathy
RMRituparna Maiti
Rituparna Maiti
DHDebasish Hota
Debasish Hota
Urinary tract infections (UTIs) present a significant health challenge for women globally, particularly due to high recurrence rates. This randomized, double-blinded, placebo-controlled study conducted at AIIMS Bhubaneswar, India, evaluated the effectiveness of a multi-strain lactobacilli probiotic formulation as an adjunct to standard antibiotic therapy in preventing recurrent UTIs. Fifty-one adult women (18–50 years) with recurrent UTIs received either the probiotic or a placebo for 24 weeks. The primary outcome was UTI recurrence, while secondary outcomes included the number of UTI episodes and changes in urinary nerve growth factor (NGF) and serum macrophage colony-stimulating factor (M-CSF) levels. The results showed a significant reduction in UTI recurrence in the probiotic group, with 75% remaining recurrence-free, compared to 33% in the placebo group (p = 0.007). The relative risk for recurrence absence was 2.67 (95% CI: 1.19–5.99). Although the mean number of UTI episodes decreased in the probiotic group, the difference was not statistically significant (p = 0.379). The urinary NGF and serum M-CSF levels significantly decreased from baseline in both groups, but there were no significant differences between them. This study suggests probiotics may be a valuable adjunct therapy for preventing recurrent UTIs.

28 August 2023 in International Journal of Developmental Neuroscience
Verified
Journal Article
Closed access
SKSneha Kimi
Sneha Kimi
RMRituparna Maiti
Rituparna Maiti
ASAnand Srinivasan
Anand Srinivasan
BMBiswa Ranjan Mishra
Biswa Ranjan Mishra
DHDebasish Hota
Debasish Hota